C4 Therapeutics Inc
NASDAQ:CCCC
C4 Therapeutics Inc
NASDAQ:CCCC
Price:
1.78
USD
-2.2%
Market Cap:
$172.5m
Relative Value
The Relative Value of one
CCCC
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 1.78 USD,
C4 Therapeutics Inc
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CCCC Relative Value
HIDDEN
Multiples Across Competitors
CCCC Competitors Multiples
C4 Therapeutics Inc Competitors
C4 Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
C4 Therapeutics Inc
NASDAQ:CCCC
|
172.5m USD | 5.7 | -1.4 | 0.2 | 0.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
396B USD | 6.7 | 169.1 | 16.4 | 23.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
202.6B USD | 5.4 | 25.8 | 14.8 | 14.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
188B USD | 6.4 | 23 | 15.6 | 15.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
119.6B USD | 10.2 | 32.5 | 23.9 | 24.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82B USD | 5.7 | 18.1 | 15.3 | 17.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
89B AUD | 4 | 20.6 | 13.8 | 17.2 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42.7B EUR | 14.3 | 33.7 | 57.5 | 59.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
